Literature DB >> 4197570

On the mode of action of BCG.

M S Mitchell, D Kirkpatrick, M B Mokyr, I Gery.   

Abstract

Mesh：

Substances：

Year:  1973        PMID： 4197570     DOI： 10.1038/newbio243216a0

Source DB:  PubMed          Journal:  Nat New Biol        ISSN： 0090-0028


× No keyword cloud information.
  20 in total

1.  Active suppression of in vitro reactivity of spleen cells after BCG treatment.

Authors:  S Orbach-Arbouys; M F Poupon
Journal:  Immunology       Date:  1978-03       Impact factor: 7.397

2.  Effect of Bacillus Calmette-Guérin on the in vitro generation of cytotoxic T lymphocytes. II. Role of interleukin-1-like factors and of soluble suppressor factors.

Authors:  L Mellow; E Sabbadini
Journal:  Immunology       Date:  1985-10       Impact factor: 7.397

3.  Immunosuppressive activity of BCG: effects of adjuvant disease, lymphocyte subpopulations, and homing of thoracic duct cells in rats.

Authors:  R I Sutherland; M A Spadaro-Antonelli; V J Lawrence; F Quagliata
Journal:  Infect Immun       Date:  1979-07       Impact factor: 3.441

4.  Immunogenicity of viable tumor cells. A comparison of xenogenized tumor cells and BCG-tumor cell mixtures.

Authors:  Y Suzuki; K Suzuki; M Hosokawa; H Kobayashi
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

5.  The immunologic and immunotherapeutic sequelae of intraperitoneal BCG. II: Serial changes in spleen weight, morphology, cell populations and in vitro mitogen responses.

Authors:  W R Roche; H McLaughlin
Journal:  Ir J Med Sci       Date:  1983-08       Impact factor: 1.568

6.  Suppression of T-cell responses to histocompatibility antigens by BCG pre-treatment.

Authors:  S Orbach-Arbouys; M Castes
Journal:  Immunology       Date:  1980-02       Impact factor: 7.397

7.  Histopathological studies on antitumor effect of sporamycin. Cell-mediated immunity against allogeneic tumor-bearing mice.

Authors:  Y Kawakubo; K Komiyama; I Umezawa; Y Nishiyama
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

8.  Solid phase activation of alternative pathway of complement by beta-1,3-glucans and its possible role for tumour regressing activity.

Authors:  J Hamuro; U Hadding; D Bitter-Suermann
Journal:  Immunology       Date:  1978-04       Impact factor: 7.397

9.  Menningococcal antigens (MA): a novel immune stimulant in experimental neoplasia.

Authors:  J A Teodorczyk-Injeyan; B G Sparkes; J M Dupuy; V V Micusan; R E Falk
Journal:  Cancer Immunol Immunother       Date:  1983       Impact factor: 6.968

10.  Dynamics of thymidine incorporation by spleen cells from rats infected with Plasmodium berghei.

Authors:  J Golenser; D T Spira; A Zuckerman
Journal:  Clin Exp Immunol       Date:  1975-11       Impact factor: 4.330
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.